Amyloid b-peptide (Ab) clearance from the central nervous system (CNS) maintains its low levels in brain. In Alzheimer's disease, Ab accumulates in brain possibly because of its faulty CNS clearance and a deficient efflux across the blood-brain barrier (BBB). By using human-specific enzyme-linked immunosorbent assays, we measured a rapid 30 mins efflux at the BBB and transport via the interstitial fluid (ISF) bulk flow of human-unlabeled Ab and of Ab transport proteins, apolipoprotein E (apoE) and apoJ in mice. We show (i) Ab40 is cleared rapidly across the BBB via low-density lipoprotein receptor-related protein (LRP)1 at a rate of 0.21 pmol/min g ISF or 6-fold faster than via the ISF flow; (ii) Ab42 is removed across the BBB at a rate 1.9-fold slower compared with Ab40; (iii) apoE, lipid-poor isoform 3, is cleared slowly via the ISF flow and across the BBB (0.03-0.04 pmol/ min g ISF), and after lipidation its transport at the BBB becomes barely detectable within 30 mins; (iv) apoJ is eliminated rapidly across the BBB (0.16 pmol/min g ISF) via LRP2. Clearance rates of unlabeled and corresponding 125 I-labeled Ab and apolipoproteins were almost identical, but could not be measured at low physiologic levels by mass spectrometry. Amyloid b-peptide 40 binding to apoE3 reduced its efflux rate at the BBB by 5.7-fold, whereas Ab42 binding to apoJ enhanced Ab42 BBB clearance rate by 83%. Thus, Ab, apoE, and apoJ are cleared from brain by different transport pathways, and apoE and apoJ may critically modify Ab clearance at the BBB.
Introduction
Amyloid b-peptide (Ab) accumulation in brain and its neuronal toxicity contribute to the pathogenesis and progression of Alzheimer's disease (AD) (Hardy and Selkoe, 2002; Zlokovic, 2005) . Recent studies from our and other laboratories suggest a major role of Ab clearance in determining Ab concentration in the central nervous system (CNS) (Selkoe, 2001; Zlokovic, 2004 Zlokovic, , 2005 Tanzi et al, 2004; Holtzman and Zlokovic, 2006) . In particular, bidirectional transport of soluble-free Ab across the blood-brain barrier (BBB) via low-density lipoprotein receptorrelated protein-1 (LRP1) (Shibata et al, 2000; Deane et al, 2004) and receptor for advanced glycation end products (Mackic et al, 1998a; Deane et al, 2003) , binding of Ab to apolipoprotein E (apoE) (Martel et al, 1997) and apoJ (Zlokovic et al, 1996) , Ab metabolism (Selkoe, 2001; Iwata et al, 2000 Iwata et al, , 2001 , and degradation by astrocytes (Wyss-Coray et al, 2003; Koistinaho et al, 2004 ) may influence Ab transport exchange at the BBB and/or its clearance from the CNS.
A microdialysis technique has been developed to measure transport exchange of an endogenous soluble pool of human Ab in brain interstitial fluid (ISF) in different transgenic models of AD (Cirrito et al, 2003) . However, the BBB bidirectional transport of exogenous soluble human Ab (Zlokovic et al, 1993; Maness et al, 1994; Ghilardi et al, 1996; Ghersi-Egea et al, 1996; Poduslo et al, 1997; Mackic et al, 1998b; Deane et al, 2003 Deane et al, , 2004 Deane et al, , 2005 Banks et al, 2003; LaRue et al, 2004) and the BBB influx of its circulating binding transport proteins (Zlokovic et al, 1996; Martel et al, 1997) have been frequently studied with 125 I-radiolabeled tracers. However, the clearance transport pathways of unlabeled exogenous Ab and apolipoproteins from brain ISF have not been studied.
Here, we modified our well-established clearance technique in mice (Shibata et al, 2000; Deane et al, 2004 Deane et al, , 2005 to determine transport routes and clearance rates across the BBB and via the ISF bulk flow of unlabeled synthetic human Ab40 and Ab42 and of Ab transport proteins, human recombinant apoE (isoform 3) and native human plasma-derived apoJ. To determine clearance of unlabeled testmolecules from the CNS, we used human-specific enzyme-linked immunosorbent assays (ELISAs). We have also explored the feasibility of matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and liquid chromatography (LC) electrospray ionization mass spectrometry (MS/MS) to determine clearance of unlabeled Ab and apolipoproteins from the CNS. Finally, we compared clearance rates of unlabeled and 125 I-labeled Ab and apolipoproteins. Our data indicate Ab, apoE, and apoJ are cleared from brain by different transport routes, and binding of Ab to apoE and apoJ may critically influence Ab efflux at the BBB and its clearance from brain.
Materials and methods

Ab and Apolipoproteins
Human Ab40 and Ab42 were synthesized and characterized as we described . Affinity-purified crude extract of human plasma apoJ ( Figure 1A) was purified by high-pressure LC (HPLC) ( Figure 1B) , as described (de Silva et al, 1990; Zlokovic et al, 1996) . The Tris/Tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10%-20%) shows a single apoJ band consisting of a and b chain ( Figure 1C ), confirmed as apoJ by MALDI-TOF (not shown). Recombinant human apoE (isoform 3) was from baculovirus-transfected Sf9 cells purchased from Invitrogen (Carlsbad, CA, USA, Cat. No. P2003). Lipidated apoE (isoform 3) was prepared from conditioned media of immortalized mouse astrocytes, as we described (Morikawa et al, 2005) . Lipid-poor apoE complex with synthetic human Ab40 was prepared as we described (Martel et al, 1997) and purified by the size exclusion fast protein LC to remove excess Ab. Amyloid bpeptide 42-apoJ complex was prepared as we described (Zlokovic et al, 1996) and purified over a fast protein LC column before use. Within the 30 mins of Ab-apoE and Ab-apoJ complex administration into brain ISF, Ab in phosphate-buffered saline-soluble brain supernatant fraction co-immunoprecipitates with anti-apoE (3D12, Biodesign International, Sako, ME, USA, Cat. No. H61529M) or anti-apoJ (A241, Quidel, San Diego, CA, USA) antibody > 98% and 99%, respectively, indicating that the peptide remains stable in the form of complexes with apolipoproteins over the period required for clearance measurements.
Clearance Technique
Mice were kept under standard housing conditions and feeding schedules until experimental procedures were performed. All studies were performed according to the National Institutes of Health guidelines using an approved institutional protocol. Briefly, a stainless-steel guide cannula was implanted stereotaxically into the right caudate-putamen of anesthetized C57Bl6 mice (100 mg/kg ketamine and 10 mg/kg xylazine intraperitoneally) with the cannula tip coordinates 0.9 mm anterior and 1.9 mm lateral to the Bregma and 2.9 mm below the surface of the brain. Animals were recovered after surgery before clearance studies. The experiments were performed before substantial chronic process occurred, as assessed by histologic analysis of tissue, that is, negative staining for astrocytes (glial fibrillar acidic protein) and activated microglia (anti-phosphotyrosine), but allowing time for the BBB repair for large molecules, as reported previously (Cirrito et al, 2003; Deane et al, 2004 Deane et al, , 2005 .
The test-molecules, unlabeled synthetic human Ab40 and Ab42, human apoE (isoform 3) non-lipidated and lipidated, and human native apoJ were administered into brain ISF simultaneously with 14 C-inulin (reference molecule) over 5 mins using our clearance technique (Shibata et al, 2000) . The test-molecules were administered in 0.5 mL mock ISF at equimolar concentrations of 40 fmol/mL corresponding to 0.173 and 0.181 ng/mL of Ab40 and Ab42, respectively, 1.40 ng/mL of apoE, nonlipidated or lipidated, and 3.20 ng/mL of apoJ. When the effects of anti-LRP1 (N20, polyclonal goat anti-human antibody that crossreacts with mouse LRP1; Santa Cruz Biotech. Inc., Santa Cruz, CA, USA), anti-LRP2 (LRP2; Rb 6286, from Dr S Argraves), and control non-immune immunoglobulin G (murine serum immunoglobulin G, Sigma, St Louis, MO, USA) on Ab or apoJ clearance were studied, these were infused at concentrations of 60 mg/mL 10 mins before and then simultaneously with the testmolecules. Receptor-associated protein (RAP) (Oxford Biomed Research, Oxford, MI, USA), which blocks both LRP1 (Shibata et al, 2000; Deane et al, 2004) and LRP2 (Zlokovic et al, 1996) , was infused at 5 mmol/L 10 mins before and then simultaneously with the test-molecules. Clearance of Ab, apoE, and apoJ was determined focally in brain by using human-specific ELISAs (see below). At predetermined times, which in most experiments was within 30 mins of intracerebral administration, brain and blood were sampled and prepared for Ab, apoE, and apoJ ELISAs. At the time of CNS administration, unlabeled Ab40 and Ab42 were negative for Ab oligomers and Ab aggregates, as shown by negative dot-blot analyses with Ab-oligomer-specific (A11) and Ab-aggregate-specific (OC) antibodies obtained from Dr Charles Glabe (data not shown).
In studies with 125 I-labeled test-molecules, the amount of injected tracers was determined using a micrometer to measure the linear displacement of the syringe plunger in the precalibrated microsyringe. Tracer fluid (0.5 mL) containing 125 -labeled test-molecules (e.g., Ab, apolipoproteins) and 14 C-inulin (reference molecule) was injected over 5 mins. To compare directly the clearance rates of 125 Ilabeled Ab and apolipoproteins with the corresponding unlabeled Ab and apolipoproteins, we administered exactly the same amounts of 125 I-labeled Ab40 (0.173 ng/ mL), Ab42 (0.181 ng/mL), apoE (1.40 ng/mL) nonlipidated and lipidated isoform 3, and apoJ (3.20 ng/mL), as in the experiments with unlabeled Ab and apolipoproteins. Brain and blood were sampled and prepared for radioactivity analysis as described (Shibata et al, 2000; . Clearance of Ab, apoE, and apoJ was determined by the radioactivity analysis (see below).
Detection of Clearance by Human-Specific Enzyme-Linked Immunosorbent Assays
Briefly, about 15 mg of brain tissue adjacent to the site of microinjection was homogenized with an extraction buffer containing 50 mmol/L NaCl, 0.2% diethylamine and complete protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Diethylamine was used as it improves Ab recovery from tissue homogenates, reduces background signal, and requires low dilution before ELISA determination (Schmidt et al, 2005) . This allows for quantification of typically low levels of soluble Ab found in tissues without plaques (Best et al, 2005; Deane et al, 2005) . Samples were centrifuged for 1 h at 100,000 g, and supernatant (pH 8.0) diluted 1:1 before adding to ELISA plates. Amyloid bpeptide 1-40 and 1-42 colorimetric kits (Invitrogen, KHB3441 and KHB3544) were used to determine Ab40 and Ab42 levels in brain extract and plasma, respectively. These kits detect whole intact Ab 1-40 and 1-42 molecules and do not recognize Ab fragments. For apoE and apoJ, polysterene microtiter plates were coated with 10 mg/mL monoclonal anti-apoE antibody (3D12) or polyclonal anti-apoJ antibody (Chemicon, Temecula, CA, USA), respectively, overnight at 41C. After blocking with 3% bovine serum albumin for 1 h at room temperature, standards and samples were added and incubated for 2 h. Bound apoE and apoJ were detected by affinity-purified biotinylated goat anti-apoE (Biodesign International, Cat. No. K74180B) and monoclonal anti-apoJ (Quidel, Cat. No. A241) antibodies, respectively, followed by streptavidinhorseradish peroxidase conjugate (Invitrogen, Cat. No. SNN2004 ) or anti-mouse-horseradish peroxidase conjugate (Sigma, Cat. No. A4789). The reaction was developed for 30 mins using tetramethyl benzidine substrate and stopped with 1 N HCl and quantified at 450 nm. The recovery of test-molecules at time zero (immediately after administration) was > 99%, which compares well with the recovery of 14 C-inulin ( > 99%) determined by the liquid scintillation spectrometry. To determine the levels of simultaneously injected 14 C-inulin, 15 mL of the brain extract was solubilized in 0.5 mL of tissue solubilizer (Perkin-Elmer, Boston, MA, USA) overnight before the addition of 5 mL of scintillation fluid (Packard Utima Gold, Perkin-Elmer), and analyzed in a liquid scintillation counter (Packard Tri-Carb 2100TR Liquid Scintillation Counter, Perkin-Elmer). The levels of Ab40 and apoE in the brain after the administration of preformed Ab40-apoE complex were determined as described above using 25 mL of the brain extract for each ELISA.
Detection of Clearance with Iodinated Ligands
Amyloid b-peptide 40 and Ab42 were iodinated using a mild lactoperoxidase method . Radiolabeled peptides were HPLC purified to eliminate free iodide, diiodinated Ab, oxidized Ab, or unlabeled Ab, as we reported (Deane et al, 2003; LaRue et al, 2004) . For clearance studies, we used only reduced monoiodinated Ab peak (specific activity B60 mCi/mg), as confirmed by MALDI-TOF MS analysis, as reported . ApoJ and apoE were labeled by Iodo-Gen (Pierce, Rockford, IL, USA, Cat. No. 28600) to specific activity of 9-12 mCi/mg. Free iodide was removed from radiolabeled apoE and apoJ preparations by gel filtration. All 125 Ilabeled molecules were used within 24 h of labeling to avoid radiolysis, as we described . The trichoracetic acid (TCA)-precipitable 125 I-radioactivity and the non-TCA precipitable 125 I-radioactivity (e.g., degraded Ab) were determined, as we reported (Shibata et al, 2000; Deane et al, 2003 Deane et al, , 2004 . Our earlier studies with 125 Ilabeled Ab have shown that both radiolabeled Ab40 and Ab42 remain mainly intact in brain ISF ( > 95%) within 30-90 mins of in vivo clearance studies (Shibata et al, 2000) , as well as during rapid clearance studies in vitro on brain capillaries , as shown by the TCA analysis and confirmed by the HPLC and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses. In the present study, the TCA, HPLC, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis/immunoprecipitation analysis confirmed previous findings, indicating that molecular forms of transport of 125 I-labeled Ab and apolipoproteins within 30 mins of clearance studies remained mainly in their original form of intact molecules ( > 98%), as injected in the CNS.
Matrix-Assisted Laser Desorption Ionization Time-of-Flight and Liquid Chromatography Electrospray Ionization Mass Spectrometry/Mass Spectrometry
To determine the limit of quantification (LOQ) for human Ab by MALDI-TOF MS, we spiked mouse CSF with various amounts of human synthetic Ab40 (0.1-30 ng/ spot) and a constant amount of metabolically labeled 15 N-Ab40 (internal standard; 30 ng/spot; R-peptide, Atlanta, GA, USA), as reported (Gelfanova et al, 2006) . Samples were mixed with an equal volume of a-cyano-4-hydroxycinnamic acid in 50% acetonitrile and spotted onto the MALDI target using a MALDI-TOF MS (Voyager-DE STR BioSpectrometry Applied Bioscience, Foster City, CA, USA). Spectra were obtained from 15 separate areas of the spot with 200 laser shots per acquisition. All acquisitions were averaged for each spot.
For LC electrospray ionization MS/MS analysis, 15 N-Ab40 was digested into tryptic peptides and applied to a microcapillary LC system (Surveyor MS Pump Plus HPLC system Thermo Corporation, San Jose, CA, USA) coupled to the linear ion-trap mass spectrometer (Thermo Corporation, San Jose, CA, USA). An in-line analytical capillary column (75 mm i.d. 10 cm) was packed using C 18 reversedphase resin (5 mm, 200 Å Magic C 18 AG, Michrom BioResource, Auburn, CA, USA) and Picofrit capillary tubing (75 mm i.d. 10 cm, New Objective, Cambridge, MA, usa). Each sample was first concentrated and de-salted by loading in solvent A (0.1% acetic acid in solution of 5% acetonitrile and 95% water) for 20 mins.
Peptides were eluted using a linear gradient of 5-70% solvent B (to a final working concentration 0.1% acetic acid in solution of 95% acetonitrile and 5% water over 70 mins, followed by isocratic elution at 95% solvent B for 10 mins, to wash the column, with a flow rate of 0.200 mL/ min across the column. Peptides eluting from the capillary column were automatically selected for collision-induced dissociation by the mass spectrometer using a datadependent protocol that alternated between one MS scan and seven MS/MS scans for the seven most abundant precursor ions detected in the MS survey scan. Precursor m/z values, selected for collision-induced dissociation using a collision energy setting of 35%, were dynamically excluded for 30 secs after selection. The mass range for precursor ion detection was set from 400 to 2000 Da. The electrospray voltage was set to 2.1 kV. The operation of the mass spectrometer was controlled by Xcalibur LC/ MS/MS software (Thermo Corporation, San Jose, CA, USA). The MS/MS spectra were sequence database searched using a database that had been indexed using 15 N modifications via SEQUEST7 and Bioworks Browser (both from Thermo Corporation, San Jose, CA, USA). Default threshold cutoffs were made using the following parameters: normalized crosscorrelation score for + 1, + 2, and + 3 charge peptides of 1.9, 2.7, and 3.5 respectively, and a DeltaCN value of 0.1. The MS/MS spectra were searched against a downloaded nonredundant human proteome sequence database from European Bioinformatics Institute (http://www.ebi.ac.uk/IPI/IPIhuman.html) to determine possible sequence correlations of known proteins for identification.
Mathematical Modeling
Transport clearance rates of unlabeled test-molecules, that is, Ab, apoE, and apoJ, across the BBB and by the ISF bulk flow were determined from the respective ELISA measurements by using transport analysis similar to that as reported for radiolabeled test-molecules (Shibata et al, 2000; Deane et al, 2004) . The concentrations of unlabeled test-molecules in the brain at time zero and at predetermined clearance times t were expressed in pmol/g ISF, assuming 1 g of brain contains 0.1 g of ISF (Zlokovic, 2005; Deane et al, 2005) . Brain recovery of studied testmolecules and of simultaneously infused 14 C-inulin (reference molecule) was calculated using
where N t is the concentration of the test-molecule or the amount of inulin at the end of experiment at time t, and N 0 is the concentration of a test-molecule or the amount of inulin injected in the brain ISF at time zero (Shibata et al, 2000) . The fractional clearance rate constant of inulin (k, min À1 ) provides measure of the ISF bulk flow (Shibata et al, 2000) , and is calculated as
In a case of Ab multiple-time efflux series with departure of the later time points ( > 30 mins) from the linear efflux phase, the concentration of unlabeled Ab in brain ISF (pmol/g ISF) at time t (Ab t ) is related to the concentration of Ab at time zero (Ab 0 ) and the rates of Ab total efflux from brain (k1) and its retention in brain (k2) by the biexponential equation,
where a1 = k2/(k1 + k2) and a2 = k1/(k1 + k2), and k1 and k2 are expressed in pmol Ab/min g ISF, as reported for radiolabeled Ab (Shibata et al, 2000) . In a case of singletime point, rapid efflux series within the 30 mins of the linear efflux of test-molecules from the brain, the concentrations of unlabeled Ab, apoE, and apoJ in the brain ISF (pmol/g ISF) at 30 mins (test-molecule t30 ) are related to the concentrations of the respective testmolecules at time zero (test-molecule t0 ) and the total rate of efflux (k3, pmol test-molecule/min g ISF) by the monoexponential equation,
as reported for radiolabeled Ab . The clearance rates of Ab, apoE, and apoJ across the BBB (pmol/min g ISF) were calculated from the single-time efflux series within 30 mins from the total efflux rates of test-molecules (k3, pmol/min g ISF; Equation (4)) and the fraction of test-molecules cleared via the ISF bulk flow determined by the clearance rate of inulin (reference molecule) given by
where test-molecule t0 is the initial concentration of the test-molecule injected into brain ISF at time zero, t 0 . The same equations were used to calculate clearance rates of radiolabeled test-tracers taking into account their respective concentrations, as we described (Shibata et al, 2000; Deane et al, 2004) . In case of 125 I-labeled Ab, apoE, and apoJ, only 125 I TCA-precipitable radioactivity was used to calculate the concentrations of intact tracers.
Statistical Analysis
Data are analyzed by multifactorial analysis of variance and Student's t-test. The differences were considered to be significant at P < 0.05. All values were mean7s.e.m.
Results
Detection of Human Ab, ApoE, and ApoJ Clearance by Human-Specific Enzyme-Linked Immunosorbent Assays Figure 2A shows disappearance curve of human synthetic unlabeled Ab40 from brain after its administration into brain ISF simultaneously with 14 C-inulin over the studied period of time of 240 mins. There was time-dependent and rapid disappearance of Ab40 from its initial levels at time zero of about 13 pmol/g ISF to almost undetectable levels at 90, 120, and 240 mins. In contrast to Ab, 14 C-inluin was cleared slowly from the brain via the ISF bulk flow (Shibata et al, 2000; Deane et al, 2004) , as indicated by its high brain retention of 74% and 52% of the injected dose at 90 and 240 mins, respectively. The levels of human Ab40 and Ab42 at the beginning of the clearance study at time zero, Ab 0 , were on average 12.8 and 13.2 pmol/g ISF, which was within the range of endogenous Ab levels in the mouse brain, as reported ( Figure 2B ) Both Ab40 and Ab42 levels decreased significantly to 5.16 and 8.64 pmol/g ISF within 30 mins, respectively, indicating clearance from the brain of both peptides, and significantly faster elimination of Ab40. The decrease in inulin within 30 mins was B10%, reflecting its passive transport via the ISF flow (Shibata et al, 2000; Deane et al, 2004) . Figure 2C shows efflux of unlabeled Ab at 30 mins is significantly inhibited ( > 70%) with centrally administered LRP1-specific antibody and RAP, but not with non-immune immunoglobulin G or anti-LRP2 (not shown). Moreover, intact human Ab40 and Ab42 were both present in mouse plasma within 30 mins of CNS administration, but were undetectable in plasma in the presence of centrally administered LRP1-specific antibody, as determined by the respective ELISAs ( Figure 2D ). These data confirm transcytosis of intact Ab peptides across the BBB and indicate that Ab efflux at the BBB is LRP1dependent, as suggested by earlier work with radiolabeled Ab (Shibata et al, 2000; Deane et al, 2004) . It is of note that plasma levels of inulin were not significantly different form zero (not shown) consistent with its slow clearance via the ISF flow. Figure 3A shows the levels of non-lipidated apoE (isoform 3) were slightly reduced from 13.1 pmol/g ISF at time zero to 10.9 pmol/g ISF at 30 mins. There was almost no difference in slope between inulin and lipidated apoE (isoform 3) within 30 mins of their simultaneous administration into brain ISF. In contrast, apoJ was cleared rapidly across the BBB as indicated by a steep decrease of its levels from 13.3 pmol/g ISF at zero time to 7.3 pmol/g ISF at 30 mins ( Figure 3B ). Figure 3C shows that Ab40 clearance from its preformed complex with lipidpoor apoE is reduced substantially at 30 mins compared with clearance of free Ab injected into brain ISF at equimolar concentration in the absence of apoE. In contrast to Ab, the levels of apoE at 30 mins of the CNS administration were comparable regardless of whether apoE (isoform 3) was injected alone or in the form of a complex with Ab. The rates of Ab, apoE, and apoJ efflux via BBB transport and the ISF flow were calculated from 30 mins series by using eqs. 2, 4, and 5 and a transport kinetic model similar to that we reported for radiolabeled Ab (Shibata et al, 2000) . Table 1 shows that transport via BBB represents a major efflux route for human Ab40 from the CNS. The rate of BBB efflux of 0.21 pmol/min g ISF was > 6-fold greater than the rate of its transport via the ISF flow consistent with the results obtained with 125 I-labeled Ab40 (Shibata et al, 2000) . The rate of Ab clearance across the BBB calculated from the multiple-time efflux series (Figure 2A) with eqs. 2, 3, and 4 was 0.22 pmol/min g ISF, which was almost identical as the rate of Ab BBB efflux obtained from a single time-point series ( Table 1 ). We also showed that the rate of Ab42 BBB efflux was 1.9-fold lower than for Ab40, although its elimination via the ISF flow was comparable with that of Ab40. Nonlipidated apoE (isoform 3) at its physiologic CSF levels was transported via the ISF flow and across the BBB at comparable low rates, that is, from 0.03 to 0.04 pmol/min g ISF, respectively. There was no detectable rapid BBB efflux of lipidated apoE3 within 30 mins, which does not rule out the possibility that lipidated apoE may be cleared from brain over longer periods of time > 30 mins. At its physiologic CSF levels of 40 fmol/mL, apoJ was cleared rapidly from brain ISF within 30 mins mainly via BBB transport at a rate of 0.16 pmol/ min g ISF. Amyloid b-peptide 40-apoE complex was cleared at the BBB at a rate 5.7-fold lower than free Ab40.
Detection of Human Ab, ApoE, and ApoJ Clearance with Radiolabeled Tracers
After our earlier work on CNS transport of exogenous Ab employed radiolabeled Ab, we studied whether CNS clearance of 125 I-labeled Ab40 and Ab42, as well as of 125 I-labeled apoE and apoJ, corresponds to clearance of the respective unlabeled test-molecules, as measured above. To compare directly the clearance rates of 125 I-labeled and unlabeled Ab and apolipoproteins, we administered exactly the same amounts (ng/mL) of 125 I-labeled Ab40, Ab42, apoE, and apoJ as in the experiments with unlabeled Ab and apolipoproteins, as explained in Materials and Methods. Figure 4A shows that within 30 mins of the CNS administration, brain recovery of the corresponding unlabeled and 125 Ilabeled Ab, apoE, and apoJ molecules were almost identical. Table 2 shows that the clearance rates via BBB transport and ISF flow of 125 I-labeled Ab40, Ab42, apoE nonlipidated, and lipidated isoform 3 and of apoJ over the 30 mins period were not significantly different from the rates of their respective unlabeled molecules (see Table 1 ). These data suggest that iodination does not alter Ab, apoE, and apoJ clearance from the CNS. Figure 4B shows that apoJ clearance from the brain was inhibited by RAP and anti-LRP2, but not by anti-LRP1, as indicated by significantly higher N t /N 0 brain retention values for apoJ in the presence of RAP and anti-LRP2. Appearance of TCA-precipitable 125 I-radioactivity in plasma after administration of 125 I-apoJ into brain ISF suggested apoJ transport from brain ISF to blood, which has been confirmed with native unlabeled apoJ by a human-specific apoJ ELISA (not shown). As apoJ is cleared faster from brain ISF than Ab42, we tested whether binding of Ab42 to apoJ may increase Ab42 clearance from the CNS. 125 I-Ab42-apoJ complex was prepared as we described (Zlokovic et al, 1996) . Figure 4C shows that Ab42 bound to apoJ was cleared faster than Ab42 alone, and clearance of Ab-apoJ complex was blocked by anti-LRP2-specific antibody. The rate of Ab42-apoJ clearance across the BBB was increased by 83% compared with Ab42 alone. Ab, amyloid b-peptide; apo, apolipoprotein; BBB, blood-brain barrier; ISF, interstitial fluid; lip-apoE3, lipidated apoE3; nonlip-apoE3, lipid-poor apoE3.
Values were calculated with Equations (2), (40), and (5). Mean7s.e.m. from 6 to 8 mice per test-molecule. *P < 0.01, Ab40-apoE compared to Ab40.
Matrix-Assisted Laser Desorption Ionization Time-of-Flight and Electrospray Ionization Mass Spectrometry/Mass Spectrometry analysis
By using the MALDI-TOF MS analysis, we obtained an LOQ of 8 ng/mL for exogenous human Ab40 in mouse CSF or artificial ISF. Since physiologic levels of exogenous Ab in focal brain clearance studies are typically achieved with microinjections of 0.5 mL mock ISF containing 0.173 ng/mL or less of Ab40 (Shibata et al, 2000; Deane et al, 2005) , to achieve the LOQ it would require concentration of CSF and brain extracts from 920 and 231 mice, respectively. Using a more sensitive serial MALDI-TOF-TOF (Gelfanova et al, 2006) , it would still require concentration of CSF from 12 mice and brain extracts from 3 mice to achieve the LOQ. By using the LC electrospray ionization MS/MS analysis, the LOQ for 15 NAb40 was 0.1732 ng/mL in mouse CSF or artificial ISF. Therefore, in a typical brain clearance study with physiologic focal levels of exogenous Ab40, concentration of CSF from 20 mice and brain extracts from 5 mice would be required to achieve this LOQ. Regarding apoE, the LOQ was 1.4 ng/mL. Thus, in a typical clearance study with exogenous apoE at low physiologic levels, the CSF from 20 mice and brain extracts from 3 mice would need to be concentrated to achieve this LOQ. The purpose of determining the LOQ for Ab and apolipoproteins was to evaluate the sensitivity of MALDI-TOF and Electrospray Ionization Mass Spectrometry/Mass Spectrometry to measure the clearance rates of Ab and apolipoproteins from the mouse CNS.
Discussion
Our data suggest that one can measure accurately the clearance rates of unlabeled human Ab and apolipoproteins across the BBB and via the ISF bulk flow in mice by using human-specific ELISAs. Matrix-assisted laser desorption ionization time-offlight mass spectrometry and LC ESI MS/MS were less sensitive than the ELISA measurements in determining the CNS clearance rates in mice of unlabeled Ab and apolipoproteins at low physiologic levels as found normally in the CSF and brain in mice and humans . The present study shows for the first time that iodination does not alter the CNS clearance measurements of Ab 1-40 and 1-42, as long as transport of 125 I-labeled Ab is measured in its monoiodinated reduced form, as reported (Deane et al, 2003 LaRue et al, 2004) . Moreover, we show for the first time that apoE and apoJ are cleared from the brain by different transport routes and at substantially different rates that the clearance of lipidated apoE is much slower than nonlipidated apoE, and that binding of Ab to these apolipoproteins may critically alter its clearance from the CNS.
The present study shows unlabeled Ab40, at the levels corresponding to those of mouse endogenous brain Ab , is removed rapidly from brain ISF via transport across the BBB at a rate of 0.21 pmol/min g ISF. Transport of unlabeled Ab40 at the BBB was mediated via LRP1, as found with 125 I-labeled Ab40 (Shibata et al, 2000; Deane et al, 2004) . As the levels of soluble, rapidly exchangeable Ab pool in brain ISF in AD mice are around 300 pmol/L ISF, as shown by microdialysis technique , given the Ab BBB efflux rate as determined in the present study, it would take about 40 secs for LRP1 to clear this Ab pool from brain ISF, assuming Ab central production and re-entry of circulating Ab into the brain (Deane et al, 2003) stop. In AD models and AD, the levels of soluble Ab in the CSF and by extension brain ISF are around 3 nM, whereas total Ab in brain including insoluble Ab is in low micromolar range, for example around 6 mmol/kg brain (Cirrito et al, 2003; DeMattos et al, 2003) . Making assumptions as above, it would take under pathologic conditions about 13 mins for LRP1 at the BBB to eliminate all soluble free Ab from brain ISF, and about 18 days to remove total Ab from brain in AD, provided all Ab could be resolubilized into its free form. Although these numbers suggest high BBB efflux capacity for free Ab, the present study indicates that the major pathogenic species of Ab, Ab42 (Selkoe, 2001) , is cleared at the BBB at a rate 1.9-fold slower than Ab40. Earlier work suggested LRP1 expression at the BBB may be substantially reduced in AD and in AD models . Thus, both of these factors may further modify elimination times of free Ab under pathologic conditions. We show lipid-poor apoE (isoform 3) is cleared slowly from brain compared with Ab40 or Ab42 mainly because of its low transport at the BBB, that is, 0.04 pmol/min g ISF. As a large part of the effect of apoE isoforms on AD and cerebral amyloid angiopathy risk is mediated by the interaction of apoE with Ab (Holtzman and Zlokovic, 2006) , and neither mouse apoE nor human apoE has an impact on the synthesis of brain Ab in AD models (Bales et al, 1997; Holtzman and Zlokovic, 2006) , we hypothesized apoE must affect clearance of Ab within or from brain. Our data show that binding of Ab40 to apoE (isoform 3) reduces by 5.7-fold its efflux rate at the BBB. The present study has been focused on apoE3 and used relatively short clearance times within the periods of 30 mins. There may be isoform-specific differences in apoE clearance from brain and in apoE-mediated retention of Ab in the brain that could possibly be revealed over the longer times allowed for the clearance measurements ( > 30 mins) than in the present study. It is well recognized that the e4 allele has a gene-dose effect on the risk and age of onset of AD and the amount of deposited Ab40 and vascular Ab load, as reviewed by Holtzman and Zlokovic (2006) . The isoformspecific effect of apoE on clearance of lipid-poor and lipidated apoE, the effects of longer efflux times on apoE clearance, and the receptors involved in mediating slow removal of apoE and apoE-Ab complexes across the BBB remain to be determined by future studies. It is interesting to note that it has been recently suggested that low-density lipoprotein receptor may be involved in regulating the CNS levels of human and mouse endogenous apoE and amyloid pathology in AD mice (Cao et al, 2006) .
Finally, we show that native apoJ is eliminated rapidly from brain ISF across the BBB at a rate lower than that of Ab40, but significantly higher than the rate of Ab42. ApoJ is the major carrier protein for Ab in biologic fluids , and its receptor LRP2 is expressed at the BBB (Zlokovic et al, 1996; Chun et al, 1999) . We hypothesized LRP2 may be involved in efflux of apoJ out of the CNS, and Ab binding to apoJ may enhance clearance of highly pathogenic Ab42. Our data show that both RAP and LRP2-specific antibody block apoJ clearance, indicating LRP2 is required for apoJ efflux at the BBB. We next show that binding of Ab42 to apoJ accelerates Ab42 clearance rate at the BBB by 83%, which again requires LRP2. It has been reported that LRP2 at the BBB is saturated from the blood side by physiologic levels of apoJ in plasma, which precludes brain influx of circulating Ab bound to apoJ across the BBB (Zlokovic et al, 1996) . In contrast, efflux of Ab42-apoJ complex from brain ISF to blood is substantial at physiologic apoJ CSF levels as shown in the present study, suggesting the net transport of soluble Ab via apoJ at the BBB favors its efflux from the brain. Consistent with the present study are findings that show lack of apoJ in AD mice may increase levels of soluble Ab in the brain (DeMattos et al, 2004) . As apoJ increases Ab neurotoxicity in AD mice (DeMattos et al, 2002) , clearance of Ab-apoJ complexes from the brain could be neuroprotective.
In conclusion, the present study highlights the importance of Ab clearance mechanisms in the CNS, suggesting that efflux of Ab from brain is controlled by different transport pathways at the BBB. The lipoprotein receptors seem to play a major role in determining the rate of Ab efflux at the BBB, either in its free form via LRP1 and/or in its bound form as a complex with apoJ via LRP2. Whether other lipoprotein receptors such as LDLR participate in slow clearance of Ab-apoE complexes at the BBB remains to be explored. Future studies should characterize in greater detail possible role of apoE/ LDLR transport interactions at the BBB and of apoJ/ LRP2 interactions in regulating the levels of soluble, as well as of deposited Ab in brain.
